FDA

Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, December 3, 2022

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization.
  • On this news, Spectrums stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.
  • Then, on July 26, 2022, F45 issued a press release entitled F45 Training Announces Strategic Update.

Kaplan Fox Continues to Investigate Potential Securities Fraud at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) - INVESTOR UPDATE

Retrieved on: 
Friday, December 2, 2022

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (Spectrum or the Company) (NASDAQ: SPPI) securities.

Key Points: 
  • NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is continuing to investigate claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (Spectrum or the Company) (NASDAQ: SPPI) securities.
  • If you purchased Spectrum securities and would like to discuss our investigation, please contact us by emailing [email protected] or by calling (212) 329-8571.
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.

Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option will have a per share exercise price equal to the closing price of a share of Better Therapeutics common stock on the Grant Date.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases.
  • Better Therapeutics clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

FLEXcon Expands Eco-Friendly Packaging Product Line with Thinner-Gauged Options

Retrieved on: 
Friday, December 2, 2022

SPENCER, Mass., Dec. 2, 2022 /PRNewswire-PRWeb/ -- FLEXcon Company, Inc., an innovator in adhesive coating and laminating, today announced the expansion of its sustainable packaging line with FLEXcon® optiFLEX® THIN ecoFOCUS™. Designed with sustainability in mind, optiFLEX® THIN ecoFOCUS™ is a line of downgauged versions of the company's other optiFLEX® ecoFOCUS™ products. The white and silver BOPP products and both PE products are the first thin products on the market to be recognized by the APR. Applications include food and beverage, personal care and cosmetics, and household chemical. By expanding their product portfolios with optiFLEX® THIN ecoFOCUS™, printers can offer their clients solutions that will help them achieve their sustainability goals without sacrificing performance.

Key Points: 
  • SPENCER, Mass., Dec.2, 2022 /PRNewswire-PRWeb/ -- FLEXcon Company, Inc., an innovator in adhesive coating and laminating, today announced the expansion of its sustainable packaging line with FLEXcon optiFLEX THIN ecoFOCUS .
  • Designed with sustainability in mind, optiFLEX THIN ecoFOCUS is a line of downgauged versions of the company's other optiFLEX ecoFOCUS products.
  • By expanding their product portfolios with optiFLEX THIN ecoFOCUS, printers can offer their clients solutions that will help them achieve their sustainability goals without sacrificing performance.
  • All products in the optiFLEX THIN ecoFOCUS line are cross-platform printable, supporting a variety of print methods to help reduce SKUs.

VYRSA Technologies Announces Worldwide Launch of the VYRSA V1™ SI Fusion System

Retrieved on: 
Friday, December 2, 2022

KING OF PRUSSIA, Pa., Dec. 2, 2022 /PRNewswire/ -- VYRSA Technologies, a specialty medical device firm, announced today the FDA clearance of the VYRSA V1™ SI Fusion System. After an extensive two 1/2-year biomechanical testing protocol, VYRSA Technologies submitted a comprehensive data set to the FDA showing overwhelming evidence of biomechanical stability in the sacroiliac joint after implantation of the VYRSA V1™ SI Fusion System.

Key Points: 
  • KING OF PRUSSIA, Pa., Dec. 2, 2022 /PRNewswire/ -- VYRSA Technologies, a specialty medical device firm, announced today the FDA clearance of the VYRSA V1 SI Fusion System.
  • After an extensive two 1/2-year biomechanical testing protocol, VYRSA Technologies submitted a comprehensive data set to the FDA showing overwhelming evidence of biomechanical stability in the sacroiliac joint after implantation of the VYRSA V1 SI Fusion System.
  • VYRSA V1 has multiple openings to allow a large volume of autogenous bone graft to be easily packed into the implant to facilitate fusion.
  • With an innovative portfolio of MIS allograft implants and innovative transfixing medical devices, VYRSA Technologies is uniquely positioned as an industry leader in sacroiliac fusion.

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Update: Kaplan Fox Continues to Investigate Potential Securities Fraud

Retrieved on: 
Friday, December 2, 2022

If you purchased Y-mAbs securities and would like to discuss our investigation, please contact us by emailing [email protected] or by calling (212) 329-8571.

Key Points: 
  • If you purchased Y-mAbs securities and would like to discuss our investigation, please contact us by emailing [email protected] or by calling (212) 329-8571.
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

Medical Tubing Global Market Report 2022: Trend Shift Toward Preventative Healthcare Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "Medical Tubing Market Size, Share & Trends Analysis Report by Product (Silicone, Polyolefins), by Application (Bulk Disposable Tubing, Catheters), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Tubing Market Size, Share & Trends Analysis Report by Product (Silicone, Polyolefins), by Application (Bulk Disposable Tubing, Catheters), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global medical tubing market size is expected to reach USD 19.50 billion by 2030.
  • The market is expected to expand at a CAGR of 5.7% from 2022 to 2030.
  • The growing middle-class population and healthcare facilities have changed the attitude of consumers toward preventive healthcare, which is expected to augment the demand for medical devices, including medical tubing, over the forecast period.

Atopic Dermatitis Treatment Global Market Report 2022: Increasing Adoption of Biological Therapies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.

Key Points: 
  • Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.
  • Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market.
  • A recent wave of biological products prescribed for treating AD will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market.
  • Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space.

Global Dermatology Medical Lasers Market 2022 to 2031 - Featuring Cynosure, Miracle Laser, Syneron and Shenzhen GSD Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.

Key Points: 
  • Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.
  • The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them.
  • The main devices of dermatology medical lasers are surgical lasers and vascular lasers.
  • Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market.

Agri-Neo's Neo-Pure Pasteurization Technology Receives TERP Validation

Retrieved on: 
Friday, December 2, 2022

TORONTO, Dec. 2, 2022 /PRNewswire-PRWeb/ -- Agri-Neo is pleased to announce that the Neo-Pure continuous food safety system, and organic pasteurization process at their Toronto Headquarters, have been validated by an ABC-approved Process Authority with agreement by ABC TERP that the Neo-Pure Food Safety System equipment and conditions used in the study demonstrate an ability to meet ABC's criteria of a minimum 4-log destruction of Salmonella bacteria on whole brownskin almonds. Agri-Neo's food safety science studies and third-party test results showed Neo-Pure meets ABC's criteria of a minimum 4-log reduction of pathogens on California almonds.

Key Points: 
  • "We are excited to provide a new pasteurization option to the California almond industry," said Rob Wong, President of Agri-Neo.
  • "Neo-Pure is a proven pasteurization technology for California almonds," said Dr. Fadi Dagher, Biochemistry Director of Agri-Neo.
  • "Neo-Pure is the only TERP-validated pasteurization technology validated using two surrogate bacteria: Pediococcus acidilactici and Enterococcus faecium.
  • The use of surrogate bacteria in food safety is considered a critical component in food safety technology validations.